Preoperative (neoadjuvant) systemic treatment of breast cancer.
暂无分享,去创建一个
[1] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Hortobagyi,et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] I. Zuna,et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] V. Semiglazov,et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Hortobagyi,et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Dowsett,et al. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial , 2003 .
[7] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[9] Hans-Peter Sinn,et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[11] Christine Solbach,et al. Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.
[12] J. Bryant,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.
[13] C. V. D. van de Velde,et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] R. Gelber,et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Eiermann,et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Powles,et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Singletary. Surgical Management of Locally Advanced Breast Cancer. , 1994, Seminars in radiation oncology.
[21] B. Asselain,et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.